Two more pharmaceutical companies have reported their performance in the third quarter, and the important window period of the pharmaceutical sector has arrived!

【Pharmaceutical Network Market Analysis】The third quarterly performance forecast of listed companies is being released
one after another.
On the evening of October 12, a number of pharmaceutical companies released their forecasts for the first three quarters of 2022, at least 2 of which are expected to achieve double growth in revenue and net profit, including WuXi AppTec and Huadong Pharmaceutical
.
2 pharmaceutical companies reported good news on the same day Huadong Pharmaceutical expects to achieve a net profit attributable to the parent of 1.
971 billion yuan to 2.
066 billion yuan in the first three quarters of 2022, a year-on-year increase of 4% to 9%; It is expected to achieve a non-net profit of 1.
868 billion yuan to 1.
938 billion yuan, a year-on-year increase of 6% to 10%.

Among them, the net profit attributable to the parent in the third quarter is expected to increase by 6% to 11% year-on-year, and the net profit after deduction of non-attributable parent is expected to increase by 7% to 15%
year-on-year.
It is understood that the growth of Huadong Pharmaceutical's performance is due to the stable development of the company's production and operation in the first three quarters of 2022, and all business segments have maintained a good growth trend
.
It is worth mentioning that during the reporting period, Huadong Pharmaceutical's medical cosmetology business continued to maintain a rapid development momentum, contributing to the overall performance growth
.
According to reports, Sinclair, as the global medical cosmetology operation entity of East China Pharmaceutical, has a new high
of consolidated operating income and EBITDA in the first half of the year.
In the domestic market, Ellansé® ® achieved an operating income of 271 million yuan in the first half of the year, and its profit level continued to improve, which has become an important growth engine
for the company's medical beauty business.
As of the mid-2022 report, Huadong Pharmaceutical has 36 "minimally invasive + non-invasive" international high-end medical cosmetology products, including 21 listed products at home and abroad, and 15 global innovative products under research, of which 11 medical cosmetology products are undergoing domestic registration related work and clinical trials
.
On the same day, WuXi AppTec expects the company to achieve operating income of about 28.
395 billion yuan in the first three quarters of this year, a year-on-year increase of about 71.
87%; The net profit was 7.
38 billion yuan, a year-on-year increase of 107.
12%.

As for the reasons for the change in performance, the company said that it was affected
by its main business.
WuXi AppTec continues to strengthen WuXi AppTec's unique integrated CRDMO and CTDMO business models.
Under the influence of the continuous and repeated epidemics in many places, give full play to the advantages of global layout, multi-location operations and full industry chain coverage, formulate and efficiently implement business continuity plans in a timely manner, and ensure the achievement
of the company's overall performance goals.
The company expressed confidence
in achieving its full-year 2022 revenue growth target of 68-72%.
The important window has arrived In the first trading week of October, 18 A-share listed companies disclosed three quarterly reports in advance, including the performance of Kangyuan Pharmaceutical
, a pharmaceutical company.
The third quarterly report of Kangyuan Pharmaceutical shows that the company achieved revenue of 3.
125 billion yuan in the first three quarters of 2022, a year-on-year increase of 20.
97%; the net profit attributable to shareholders of listed companies was 281 million yuan, a year-on-year increase of 35.
83%; Basic earnings per share were $
0.
49.
As an important window period, institutional sources said that combined with the current valuation level of A-shares, the market will focus on the main line of the three quarterly reports to explore opportunities
from high-growth companies.
Industrial Securities pointed out in a recent research report that the pharmaceutical sector has entered the third quarterly performance period, and the cost performance of the sector is outstanding
.
According to preliminary analysis, the performance of the pharmaceutical sector in the third quarter continued to grow relatively steadily and rapidly, and some subdivisions were affected by the epidemic in Q2, and Q3 showed a state of improvement compared with the previous quarter
.
Considering the current low valuation caused by the early sector adjustment, and the valuation switch will be gradually carried out in the future, the pharmaceutical sector is cost-effective
.
In terms of segmentation, the bank expects that Q3 of the upstream life sciences, ophthalmic optometry, some domestic alternative medical devices, CXO, some vaccines, pharmacies and other sectors is expected to achieve good performance growth
.
Founder Securities also believes that the current biomedical valuation is cost-effective, and short-term recommendations focus on subdivisions with high performance growth or expected to exceed expectations, such as devices and equipment, chain pharmacies, APIs, traditional Chinese medicine, etc
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.